{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:27:00Z","timestamp":1788791220324,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>IgA-mediated Anti-Laminin-\u03b31 (p200) pemphigoid is a rare subtype of subepidermal autoimmune blistering disease (AIBD) characterized by IgA autoantibodies targeting the laminin \u03b31 chain, a 200 kDa protein located at the dermal-epidermal junction. Patients typically exhibit skin-dominant blistering lesions, also mucosal involvement has been reported. We report a 73-year-old male patient diagnosed with IgA-mediated anti-Laminin-\u03b31 (p200) pemphigoid. He initially presented with prominent palmoplantar blisters erosions on the eyelids, lips and face, accompanied by mild pruritus. Skin biopsy demonstrated hyperkeratosis, parakeratosis, acanthosis, subepidermal blister formation, and mild perivascular lymphocytic infiltration in the superficial dermis. Direct immunofluorescence showed C3 deposits on the basement membrane. The patient was initially treated successfully with methylprednisolone. During the second recurrence, he presented with annular erythema topped with blisters and erosions on the lips. Comprehensive pemphigus and pemphigoid antibodies panel test showed Laminin \u03b31 IgA with a titer of 1:10. The rash recurred when corticosteroids were tapered. The patient was then treated with Stapokibart (CM310) in combination with corticosteroids, leading to complete resolution of the skin lesions and successful tapering of the corticosteroids. This case represents the first successful treatment of IgA-mediated anti-Laminin-\u03b31 (p200) pemphigoid using Stapokibart in combination with corticosteroid.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1767277","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:45Z","timestamp":1769496105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case report of IgA-mediated anti-Laminin-\u03b31 (p200) pemphigoid successfully treated with stapokibart combined with corticosteroids"],"prefix":"10.3389","volume":"17","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohuai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, the National Health Commission Key Laboratory of Medical Immunology, Medicine Innovation Center for Fundamental Research on Major Immunology-related Diseases, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, the National Health Commission Key Laboratory of Medical Immunology, Medicine Innovation Center for Fundamental Research on Major Immunology-related Diseases, Peking University","place":["Beijing, China"]},{"name":"Center for Human Disease Genomics, Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shenzhen People\u2019s Hospital, Guangdong","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.303","article-title":"IgA anti-p200 pemphigoid","volume":"147","author":"Wozniak","year":"2011","journal-title":"Arch Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1478318","article-title":"Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases","volume":"15","author":"Kowalewski","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118846","article-title":"Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid","volume":"14","author":"Gao","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903174","article-title":"Case Report: Mucous Membrane Pemphigoid With IgG and IgA Anti-Laminin gamma1 Antibodies and IgA Anti-Laminin alpha5 Antibodies","volume":"13","author":"Kuang","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15644","article-title":"Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis","volume":"23","author":"Mar","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1220887","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.16368","article-title":"Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial","volume":"80","author":"Zhao","year":"2025","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.12515","article-title":"Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 randomized clinical trial","volume":"334","author":"Shen","year":"2025","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03651-5","article-title":"Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201163","article-title":"Case Report: Prurigo nodularis-like linear IgA\/IgG bullous dermatosis: a case report and literature review","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.06.007","article-title":"Pathogenic activation and therapeutic blockage of fc\u03b1R-expressing polymorphonuclear leukocytes in IgA pemphigus","volume":"141","author":"Emtenani","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.014","article-title":"Laminin beta4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid","volume":"90","author":"Goletz","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jid.2024.08.004","article-title":"Anti-Laminin beta4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin alpha3 and gamma1\/2 Chains","volume":"145","author":"Pigors","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.014","article-title":"Laminin \u03b24 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid","volume":"90","author":"Goletz","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903174","article-title":"Case report: mucous membrane pemphigoid with IgG and IgA Anti-Laminin \u03b31 antibodies and IgA Anti-Laminin \u03b15 antibodies","volume":"13","author":"Kuang","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jid.2024.08.004","article-title":"Anti-Laminin \u03b24 IgG drives tissue damage in anti-p200 pemphigoid and shows interactions with laminin \u03b13 and \u03b31\/2 chains","volume":"145","author":"Pigors","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0136","article-title":"Bullous autoimmune dermatoses\u2013clinical features, diagnostic evaluation, and treatment options","volume":"118","author":"Beek","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jaad.2020.05.161","article-title":"Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy","volume":"85","author":"Montagnon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537428","article-title":"Pemphigoid disease model systems for clinical translation","volume":"16","author":"Tigges","year":"2025","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1118539","article-title":"Antagonizing FcalphaR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity","volume":"14","author":"van Delft","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02151-7","article-title":"Stapokibart: first approval","volume":"85","author":"Shirley","year":"2025","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf455","article-title":"Safety and efficacy of stapokibart, an anti-IL-4R\u03b1 monoclonal antibody, in children aged 6\u201311 years with moderate-to-severe atopic dermatitis: An open-label, single-arm phase 1b\/2a trial","author":"Zhao","year":"2025","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00668-z","article-title":"Long-term efficacy and safety of stapokibart in adults with moderate-to-severe atopic dermatitis: an open-label extension, nonrandomized clinical trial","volume":"38","author":"Zhao","year":"2024","journal-title":"BioDrugs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102467","article-title":"Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial","volume":"69","author":"Zhang","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:46Z","timestamp":1769496106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1767277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1767277"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1767277","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1767277"}}